您当前的位置：
首页 >
文章列表页 >
Clinical rapid evaluation of proprotein convertase subtilisin/kexin type 9 inhibitors for hypercholesterolemia
更新时间：2026-01-24

    • Clinical rapid evaluation of proprotein convertase subtilisin/kexin type 9 inhibitors for hypercholesterolemia

    • “The latest research shows that Elomumab performs the best in treating hypercholesterolemia and is the preferred drug.”
    • ZHONGGUO YAOFANG   Vol. 37, Issue 2, Pages: 149-154(2026)

    • DOI：10.6039/j.issn.1001-0408.2026.02.03    

      CLC： R972.6;R589.2

    • Received：02 September 2025，

      Revised：2025-12-26，

      Accepted：29 December 2025，

      Published：30 January 2026

    移动端阅览

  • YAO Xin,KANG Fengjiao,YIN Qinan,et al.Clinical rapid evaluation of proprotein convertase subtilisin/kexin type 9 inhibitors for hypercholesterolemia[J].ZHONGGUO YAOFANG,2026,37(02):149-154. DOI： 10.6039/j.issn.1001-0408.2026.02.03.

  •  
  •  

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Systematic review of pharmacoeconomic evaluation on PCSK9 inhibitors for the prevention of cardiovascular disease in patients with hypercholesterolemia

Related Author

ZHOU Jiancheng
ZOU Ying
WANG Luying
CHEN Pingyu
FU Yuanyuan
WANG Yongqing

Related Institution

Dept. of Pharmacy， the First Affiliated Hospital of Nanjing Medical University
School of Pharmacy， Nanjing Medical University
School of International Pharmaceutical Business， China Pharmaceutical University
0